Cosmetic cross-reference Noindex: medium evidence

14233-37-5

CAS 14233-37-5

14233-37-5 (CAS 14233-37-5) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
14233-37-5
CAS Number
14233-37-5
UNII
NEH7L3Y1P1
InChIKey
BLFZMXOCPASACY-UHFFFAOYSA-N
ChEMBL ID
CHEMBL3182568
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 14233-37-5 used for in pharmaceutical contexts?

14233-37-5 (CAS 14233-37-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 14233-37-5?

No adverse-event association or SIDER side-effect rows are rendered for 14233-37-5 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 14233-37-5 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Lauramido Diacetate with EU status "permitted".

What clinical phase is 14233-37-5 in?

No phase 1-4 clinical development badge is rendered for 14233-37-5 because the matched compound identifier rows do not contain a max-phase value.